CROWN: lorlatinib in treatment-naïve patients with ALK-positive advanced NSCLC VJOncology 2:37 2 years ago 1 165 Скачать Далее
Real-world toxicities associated with lorlatinib in ALK+ NSCLC VJOncology 1:35 2 years ago 834 Скачать Далее
Lorlatinib safe and effective for ALK-driven relapsed high-risk neuroblastoma Medical Dialogues 2:00 1 year ago 445 Скачать Далее
ESMO 2020 Highlights on 1st line lorlatinib for ALK+ NSCLC: The CROWN Study European Society for Medical Oncology (ESMO) 2:39 3 years ago 2 371 Скачать Далее
Lorlatinib as First-Line Treatment for ALK-Positive Advanced Lung Cancer PracticeUpdate 6:14 3 years ago 1 617 Скачать Далее
Efficacy of lorlatinib in NSCLC post-second generation ALK TKI VJOncology 1:30 4 years ago 513 Скачать Далее
What is Lorlatinib (Lobrena)? Lorlatinib side effects Diseases and Medicines 2:58 7 months ago 314 Скачать Далее
ALK Positive Lung Cancer in 2023 and Beyond: Thinking Outside the Box with Dr. Alice Shaw ALK Positive Inc. 42:31 11 months ago 4 523 Скачать Далее
Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma St. Jude Children's Research Hospital 2:52 3 years ago 1 725 Скачать Далее
Lorlatinib takes CROWN in head-to-head comparison with crizotinib | Benjamin Solomon Medicine Matters oncology 3:43 3 years ago 635 Скачать Далее
FDA D.I.S.C.O. Burst Edition: Lorbrena (lorlatinib) for patients with metastatic non-small cell l... U.S. Food and Drug Administration 4:01 4 months ago 105 Скачать Далее
Q&A: New Lesions - Switch from Alectinib to Lorlatinib? Targeted Therapies in Lung Cancer 2023 GRACE - Global Resource for Advancing Cancer Education 3:12 11 months ago 258 Скачать Далее
CROWN: biomarkers for lorlatinib response in patients with ALK+ NSCLC VJOncology 4:11 3 years ago 366 Скачать Далее